Antihypertensives are the drugs that are used to treat high blood pressure. Increase in blood pressure is measured in terms of systolic and diastolic blood pressure exerted by blood on the wall of artery and hence it is also termed as arterial hypertension. Antihypertensive drugs alleviate the complications of stroke and myocardial infarction. Reduction in blood pressure minimizes the risk of heart failure, ischaemic heart diseases, dementia and mortality due to hypertension. Changes in lifestyle are the prime factors that increase the number hypertensive cases. A complete analysis of the global antihypertensives market provides various aspects of market research such as market trends, market drivers, restrains and opportunities. In-depth segmental analysis helps to understand the market dynamics and would be beneficial to professionals in their decision making. The competitive landscape section focuses on key leaders within the global antihypertensives market and their major growth strategies. 

Global antihypertensives market is driven by increased epidemic proportion of hypertension around the world. Changes in lifestyle, food habits and augmented stress levels have largely responsible to increase the number of hypertensive people. The global antihypertensive market is expected to show steady growth during the forecast period due to patent expiration of major antihypertensive drugs. The market could also face the challenges due to increased threat of genericization and growing competition. A steady increase in pulmonary arterial hypertension and use of fixed dose combination therapies is expected to drive the future growth of antihypertensives market. Launch of novel drug therapies with improved safety and efficacy could also boost the market growth in the near future.

Global Antihypertensives Market by Therapeutics

The global antihypertensives market is segmented by therapeutics into different categories such as Diuretics, Angiotensin receptor blockers (ARBs), Angiotensin converting enzyme (ACE) inhibitors, Beta blockers, Alpha blockers, Calcium channel blockers, Renin inhibitors and Vasodilators. Diuretics hold the largest market share for antihypertensives, as it is the first line of treatment for hypertension recommended by most of the physicians. However, selection and suitability of drug candidate is based on patient’s medical history and current symptoms. Beta blocker, Calcium channel blocker ad ACE inhibitors are also a popular drug class form antihypertensives and used as first line of treatment in some cases. 

Global Antihypertensives Market by Geography

Geographically, global antihypertensives market is segmented into North America, Europe, Asia-Pacific and LAMEA. North America and Europe dominates the global antihypertensives market. Europe has high prevalence of hypertension, which is the primary cause of mortality and disability amongst people. Also in US, blood pressure is one of the major factors that has high mortality rate. Asia-Pacific is the lucrative geographic segment for antihypertensive drug manufacturers due to high incidences of cardiovascular diseases, government support and improving healthcare conditions.  

 
Competitive Landscape

Pfizer Inc., Novartis AG, Sanofi S.A., Merck & Co., Boehringer Ingelheim, Lupin Limited, Johnson & Johnson Ltd.,  Astra Zeneca Plc, Daiichi Sankyo Company Limited and Ranbaxy Laboratories Limited, Inc. are some of the key players of global antihypertensives market. Over the past few years, the patent expiration of major brands, namely Revatio, Diovan, Exforge and Avapro has led to high genericization of antihypertensives market. The novel antihypertensive drugs, which are in pipeline research, are expected to partly regain the losses due to patent expiration. These novel therapies include Actos, Macitentan, Riociguat, SPP635, ACT-293987, LCZ696 and others.

High Level Analysis 

A comprehensive analysis of the global antihypertensives market provides an overview of the market and its key concerns. The market segmentation section provides a deep-dive analysis of Therapeutics and geography segments, which would be helpful in understanding niche market trends. Market dynamics include market drivers, restraints and opportunities, which would help to simplify and better understand market behavior. Porter’s Five Forces analysis would be helpful to strategists to determine market profitability. Genericization of the drugs has introduced the cheaper versions of original brands and offered the cost effectiveness to the buyers. This factor strengthens the buyer’s power.  Patent expiration of blockbuster drugs has offered an opportunity for local players to enter the market, which has also contributed to make the industrial rivalry intense. 

KEY BENEFITS

• This report offers the following benefits in particular:

• Comprehensive coverage of global antihypertensives market along with disease overview, market trends, drivers and restraints would provide key insights to market dynamics

• Thorough attention is given to leading company portfolios, pipeline research, new launches and competitive landscape of top players

• Explicit information on current clinical trials and R&D activities would be beneficial to understand the future market trends  

• Insightful analysis of different segments helps to recognize and capitalize future opportunities within global antihypertensives market

KEY DELIVERABLES

The global antihypertensives market is segmented into two major categories such as therapeutics and Geography. 

MARKET BY THERAPEUTICS

• Diuretics 

• Angiotensin receptor blockers (ARBs) 

• Angiotensin converting enzyme (ACE) inhibitors 

• Beta blockers

• Alpha blockers

• Calcium channel blockers 

• Renin inhibitors

• Vasodilators 

MARKET BY GEOGRAPHY

• North America

• Europe

• Asia-Pacific

• LAMEA